A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
- PMID: 19144992
- DOI: 10.1182/blood-2007-11-126664
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML
Abstract
Currently, FLT3 tyrosine kinase inhibitors (TKIs) are emerging as the most promising drug therapy to overcome the dismal prognosis of acute myelogenous leukemia (AML) patients harboring internal tandem duplications (ITDs) of FLT3. However, up-front drug resistance occurs in approximately 30% of patients, and molecular mechanisms of resistance are poorly understood. Here, we have uncovered a novel mechanism of primary resistance to FLT3 TKIs in AML: an FLT3 receptor harboring a nonjuxtamembrane ITD atypically integrating into the beta-2 sheet of the first kinase domain (FLT3_ITD627E) induces dramatic up-regulation of the anti-apoptotic myeloid cell leukemia 1 protein (MCL-1). Using RNA interference technology, deregulated MCL-1 protein expression was shown to play a major role in conferring the resistance phenotype of 32D_ITD627E cells. Enhanced and sustained binding of the adaptor protein GRB-2 to the FLT3_ITD627E receptor is involved in MCL-1 up-regulation and is independent from TKI (PKC412)-induced inhibition of the receptor kinase. Thus, we describe a new mechanism of primary resistance to TKIs, which operates by reprogramming local and distant signal transduction events of the FLT3 tyrosine kinase. The data presented suggest that particular ITDs of FLT3 may be associated with rewired signaling and differential responsiveness to TKIs.
Comment in
-
Fathoming flt3.Blood. 2009 Apr 23;113(17):3889-90. doi: 10.1182/blood-2009-02-205435. Blood. 2009. PMID: 19389891 No abstract available.
Similar articles
-
Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.Ann Hematol. 2010 Jul;89(7):653-62. doi: 10.1007/s00277-009-0889-1. Epub 2010 Jan 30. Ann Hematol. 2010. PMID: 20119833
-
CCL5 mediates _target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML.Mol Oncol. 2020 Apr;14(4):779-794. doi: 10.1002/1878-0261.12640. Epub 2020 Feb 13. Mol Oncol. 2020. PMID: 31955503 Free PMC article.
-
Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells.PLoS One. 2011;6(9):e25351. doi: 10.1371/journal.pone.0025351. Epub 2011 Sep 28. PLoS One. 2011. PMID: 21980431 Free PMC article.
-
The Future of _targeting FLT3 Activation in AML.Curr Hematol Malig Rep. 2017 Jun;12(3):153-167. doi: 10.1007/s11899-017-0381-2. Curr Hematol Malig Rep. 2017. PMID: 28421420 Review.
-
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30. Expert Rev Hematol. 2017. PMID: 29069942 Review.
Cited by
-
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.Front Oncol. 2022 Sep 14;12:996438. doi: 10.3389/fonc.2022.996438. eCollection 2022. Front Oncol. 2022. PMID: 36185253 Free PMC article. Review.
-
BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML.Br J Cancer. 2012 Jan 31;106(3):475-81. doi: 10.1038/bjc.2011.564. Epub 2011 Dec 20. Br J Cancer. 2012. PMID: 22187040 Free PMC article.
-
_targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.Int J Mol Sci. 2018 Oct 16;19(10):3198. doi: 10.3390/ijms19103198. Int J Mol Sci. 2018. PMID: 30332834 Free PMC article. Review.
-
MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation.Tumour Biol. 2016 May;37(5):6065-72. doi: 10.1007/s13277-015-4380-4. Epub 2015 Nov 25. Tumour Biol. 2016. PMID: 26608370
-
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.Mol Cancer. 2013 Mar 7;12:19. doi: 10.1186/1476-4598-12-19. Mol Cancer. 2013. PMID: 23497317 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous